CAR-T Meeting 2021 | Progression of CAR-T trials in China
Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, gives an overview of the current CAR T-cell trial activities in China. Prof. Wang highlights the progression of the bispecific CAR-T targeting CD19 and CD22 and the BCMA and CD19 bispecific CAR-T, both manufactured in the FasT CAR-T platform. A novel TCR-based extracellular complex, STAR (synthetic TCR and antigen receptor), is being investigated in China. STAR T-cells may have improved persistence after infusion. Lastly, Prof. Wang discusses a new CD7-CAR T-cell product against T-cell malignancies. This interview took place during the 3rd European CAR T-cell Meeting.
Transcript (edited for clarity)
Last year, in the second CAR-T meeting, I presented the data related the acute lymphoblastic leukemia using the CD19 antigen CAR and also using the CD19/CD22 combination CARs. Also for the myeloma, I presented the BCMA and the BCMA combined with CD38.
Also, last year, I reported FasT CD19 CAR. But this year, I will show some data about some progression in FasT by specific CAR. This is very normal...
Last year, in the second CAR-T meeting, I presented the data related the acute lymphoblastic leukemia using the CD19 antigen CAR and also using the CD19/CD22 combination CARs. Also for the myeloma, I presented the BCMA and the BCMA combined with CD38.
Also, last year, I reported FasT CD19 CAR. But this year, I will show some data about some progression in FasT by specific CAR. This is very normal. For us, is a FasT, and second, FasT combination with bispecifc, means dual target. That’s including the CD19 and CD22 together put in one CAR and another, bispecific, FasT CAR is BCMA and CD19 against myeloma.
Also, I report the normal structure of CAR, the basic structure of CAR. But also integrated the TCR structure together, the STAR CAR. We have the integrated property of TCR. Perhaps, this kind of the STAR CAR may be persistent in the body for longer time.
Also, this year, I’ve introduced a new target CAR, especially CD7 against T-cell malignancies. So, this new information I bring here this year for the third EMBT CAR-T meeting.
Read more...
Disclosures
Advisor for Abbvie
